Direct Oral Anticoagulants in Antithrombin Deficiency: Initial Experience in a Single Center

Recently, a paper on the treatment of venous thromboembolism (VTE) in patients with hereditary antithrombin (AT) deficiency was published.[1] One of the issues the authors address is the use of direct oral anticoagulants (DOACs) and the duration of anticoagulation therapy in this specific patient population. Currently, clinical evidence on the use of DOACs in these patients is lacking. Here, we would like to share our experience with a direct factor Xa inhibitor in the treatment of VTE in our patients with hereditary AT deficiency.